



Human immunodeficiency virus (HIV) infection is caused 
by a virus that belongs to the family retroviridae, affecting 
the immune state and depleting the natural defense system.[1] 
HIV destroys the CD4 T-lymphocytes leading to cell-mediated 
immune incompetence known as Acquired Immune Deficiency 
Syndrome (AIDS) and even death.[1] In 2018, about 36.9 
million people and about 1.8 million children <15 years 
were living with HIV in the same year.[2] It was estimated 
that 940,000 people living with HIV died from AIDS-related 
illnesses worldwide in 2018.[2] The majority of the people living 
with HIV (PLHIV) live in developing countries.[2]
In Sub-Saharan Africa, about 25.5 million people were 
infected with HIV and reside in Africa.[3] Among PLHIV 
globally, Nigeria has the second-largest HIV disease burden 
with 3.1 million people after South Africa which has an 
estimate of 6.8 million people living with HIV.[3] However, 
a current published Nigeria HIV/AIDS Indicator and Impact 
Survey, one of the largest population-based HIV/AIDS 
household surveys ever conducted, found the prevalence 
to be 1.4%.[4] Better surveillance was responsible for the 
apparent decline.[4] Approximately 150,000 people died from 
AIDS-related illnesses in Nigeria in 2017.[4] Mother-to-child 
transmission of HIV accounts for over 90% of paediatric HIV 
transmission in Sub-Saharan Africa.[2] Children can also be 
infected through contaminated and unsterilized needles and 
blood transfusions and sexual abuse.[5]
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With the introduction of antiretroviral therapy (ART), there 
was a reduction in HIV replication, preservation of CD4 
T-lymphocyte cell count/function, and restoration of immunity 
to fight infection, thereby promoting or restoring normal 
growth and development, as well as improving quality of 
life.[6-8] This led to a reduction in mortality and morbidity of 
HIV-infected children/adolescents as well as an increase in the 
number of adolescents living with HIV.[8]
Symptomatic HIV infection in children is associated with 
initial and subsequent reductions in weight, height, and 
body mass index (BMI).[9] It has been reported that delayed 
physical growth in HIV-infected children/adolescents results 
in poor self-image and low self-esteem mainly when they are 
among their peers.[9] This may be related to the psychological 
and social change experienced during adolescence, whereby 
the adolescent spends time thinking about physical growth 
and body image because they want peers’ acceptance. Some 
studies have reported that males were more vulnerable to 
poor growth than females and called for further research 
into this finding.[10-12] Furthermore, the existing studies on 
assessing physical growth in male adolescents infected with 
HIV were reported in developed countries.[13-15] The study 
aimed to assess physical growth in HIV-infected males aged 
8–17 years in Abakaliki. It hopes to provide information that 
will guide paediatricians in counselling caregivers and/or 
HIV-infected adolescents. It will also provide data that may 
help create awareness and sensitization in the community on 
early diagnosis and prompt enrollment in HIV care.
Methods
Study area
This study was conducted in the paediatric HIV clinic and 
children outpatient (CHOP) department of the Federal 
Teaching Hospital, Abakaliki (FETHA) and Mile Four Mission 
Hospital, Abakaliki, Ebonyi State.
Study population
The study populations were male children infected with HIV 
attending the paediatric HIV specialty clinic in both hospitals 
aged 8–17 years, while the controls were HIV-uninfected males 
aged 8–17 years who were matched for age and socioeconomic 
class in both hospitals who were without chronic kidney 
disease, sickle cell anemia (SCA), asthma, chronic liver 
disease, and cerebral palsy attending the CHOP clinic.
Sample size determination
Sample size was determined using Jaykan and Tamoghna 
method.[16]
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Where r = ratio of control to cases (subjects), 1 for an equal 
number of cases and control.
P* = Average proportion exposed
Proportion of exposed cases +proportion of controlexposed
2
50% (0.5) was used when there was no recognizable estimate.
Zβ = normal standard variate for significant level as identified 
in the previous section. i.e., normal standard variate for the 
power of 80%, which is equal to 0.84.
Zα/2 = normal standard variate for significant level as identified 
in the previous section, i.e., normal standard variate at 95% 
confidence level = 1.96.
P1 − P2 = different in proportions or effect size identified from 
previous studies.
P1 = is proportion in cases (subjects) (0.17).
[17]
P2 = is proportion in controls (0.04).
[17]
n = minimum sample size.
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Furthermore, a second formula[18] correcting the sample size 
for a finite population was used because the first formula 
was drawn from a finite population of HIV‑infected children 





nf = represent sample size for a finite population.
n = represent a population greater than 10,000 participants.
nE = estimated total number of HIV-infected males aged 
8–17 years in FETHA and Mile Four Hospital were 











Therefore, the actual minimum sample size of cases (subjects) 
was 80.
However, the sample size was allocated proportionally (William, 
1977) to the two hospitals under study thus:
Let N1 be the number of HIV patients aged 8–17 years in 
FETHA and N2 be the number of HIV patients aged 8–17 years 
Mile four, n = minimum sample size = 80, and N total number 
of HIV patients aged 8–17 years in the two hospitals = 105. 
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The same proportion was used for the selection of the control.
Study design
The study is a case–control hospital-based study.
Study duration
The research work was carried out within six months (September 
2018 to February 2019).
Sampling method
All eligible study participants scheduled for Mondays and 
Thursdays in FETHA, Thursdays in Mile Four Mission 
Hospital, and children attending CHOP were consecutively 
enrolled until the estimated minimum sample size was reached.
Study procedure
Males infected with HIV aged 8–17 years (subjects) who met 
the inclusion criteria were enrolled consecutively during the 
weekly paediatric HIV clinic. Before recruitment into the 
study, the researcher obtained informed consent from the 
parents/caregivers and assent from the populations. At this 
stage, the details and reason for the study were explained 
to the researcher’s populations and their caregivers. The 
caregivers were also informed that participation in this study 
was voluntary, and they would not be penalized if they refuse 
to give consent/assent for participation. After that, a Case 
records containing detailed information on the biodata of the 
subject, history of diagnosis, sociodemographic profile, and 
relevant laboratory data including CD4 count and viral load 
was then completed by the researcher.
Oyedeji Social Classification System[19] was used to determine 
the social class of each participant. They were then subdivided 
into the upper, middle, and lower socioeconomic classes. Those 
in upper social class were represented by classes 1 and 2, 3 for 
the middle class, while classes 4 and 5 were defined as lower 
social class. Each score has two variables, occupation, and 
level of education of both parents/caregivers.[19]
The clinical staging and immunological classification of 
subjects into the paediatric HIV clinic were retrieved from 
the children’s case notes. The WHO clinical staging was as 
documented by WHO case definitions for clinical staging 
system and HIV surveillance in children.[20] Recognized 
clinical features were used to group them from Stage 1 
(asymptomatic) to Stage 4 (AIDS) according to WHO 
criteria.[20] The subjects were assigned to a specific stage if 
they had at least one clinical feature in that stage’s criteria. The 
WHO immunological classification was categorized from “not 
significant suppression” to “severe suppression” based on the 
revised immunological classification for HIV‑related disease in 
children and adolescents using absolute CD4+ T-lymphocyte 
counts. Stage 1 (not significant) represented CD4 cell count 
of >500 cells/mm3, stage 2 (mild) represented CD4 cell count 
of 350–499 cells/mm3, stage 3 (advanced) represented CD4 cell 
count of 200–349 cells/mm3, while stage 4 (severe) represented 
CD4 cell count of < 200 cells/mm3.[20]
The HIV-uninfected males (controls) matched for age and 
social class were enrolled from the CHOP clinic of both 
hospitals after informed consent from parents/caregivers and 
assent from the controls had been retrieved by the researcher. 
For HIV counselling and testing, the controls had a pretest 
counselling which was done routinely by the treatment support 
staff, and then, they had serial consecutive rapid diagnostic 
tests according to the National guideline on HIV counselling 
and testing to determine their HIV status.[21] To confirm the 
HIV status of the child, the initial positive test was followed 
by one more confirmatory test (Unigold™ with a sensitivity 
of 100% and specificity of 99.7%).[22] If the second test was 
negative, a third tie-breaker test was then used, which has a 
sensitivity of 100% and specificity of 100% to confirm the HIV 
status.[19] Post‑test counselling was done. Controls confirmed 
to be HIV infected were referred to the paediatric HIV clinic 
for further counselling and enrolled in HIV care. On the other 
hand, the HIV-uninfected controls were also counselled and 
subsequently enrolled and matched for age and social class 
with the subjects (HIV-infected). A case record form was then 
completed for them by the researcher. None of the controls 
enrolled was HIV positive.
The researchers measured the weight and height of both the 
subjects and controls to determine the physical growth. The 
study participants stood erect on a battery-powered digital scale 
set to the nearest 0.1 kg wearing only light clothing and leaning 
on nothing while their weight was read off from the scale and 
recorded on the case form.[23] After every ten readings, the scale 
was reset to zero to avoid errors. A known weight was placed 
on the scale every day before use and periodically while in use.
We measured the heights of the study population using the 
stadiometer.[23] Each participant was bare footed, stood erect, 
With heels brought together, and the back as straight as possible 
while the back of the head, shoulders, buttocks, and heels were 
touching the wall. As the headpiece was moved down to touch 
the child’s head, the eye–ear plane was placed perpendicular 
to the wall, and readings were recorded on the case form. The 
measurements were then recorded to the nearest 0.1 cm.







The weight, height, and BMI for age Z scores were determined 
and compared with the WHO 2007 reference values using the 
WHO AnthroPlus Software.[24-28]
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Table 1: Clinical characteristics of the subjects
Characteristics Categories Frequency (%)
ART regimen First line 64 (80.00)
Second line 16 (20.00)
Duration on ART Less than six months 3 (3.75)
Six months to five years 36 (45.00)
Greater than five years 41 (51.25)












Viral load Suppressed 34 (44.20)
Unsuppressed 43 (55.80)
Total 77 (100.00)
Not significant: >500 ml/mm3, Mild: (350-499) ml/mm3, 
Advanced: (200-349) ml/mm3, Severe: <200 ml/mm3, 
Suppressed: ≤1000 copies/ml, Unsuppressed: >1000 copies/ml. 
ART: Antiretroviral therapy
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Ethical approval
Before commencing the study, the institutional ethical approval 
was obtained from the Research and Ethics Committee of 
the FETHA and a permission letter from Mile Four Mission 
Hospital.
Confidentiality
The confidentiality of information and data retrieved from the 
study participants were emphasized to all study participants 
and were kept throughout and after the study. All the 
essential data relating to the survey were kept safe by the 
principal investigator. The study participants were assigned 
identification numbers and their data coded using their initials 
and identification numbers.
Data analysis
The data obtained was transferred into an electronic database 
using the Statistical Package for the Social Sciences (SPSS) 
version 20.0 (IBM SPSS Statistics for Windows, version 20.0. 
Armonk, NY: IBM Corp) and then analyzed. The difference 
in means for continuous variables (age, height, weight, and 
BMI) for controls and subjects was compared using Student’s 
t-test. The odds ratio was used to ascertain the odd in favor 
of the controls over the subjects. The effect of social class, 
immunological status, clinical stage, and duration on highly 
active ART (HAART) on physical growth was modeled 
using multivariate and logistic regression, respectively. The 
relationship between physical growth and viral load was tested 
using the Chi-square. All test statistics were conducted at a 
0.05 level of significance. Charts and tables were used in the 
presentation of the results.
Results
The age and social class of the study participants
One hundred and seventy-two males comprising 82 HIV 
infected (subjects) and 90 HIV-uninfected (controls) were 
recruited over six months (September 2018 to February 
2019). Two males out of the 82 subjects were excluded from 
the study because parents/caregivers did not give consent, 
while 10 males out of the 90 controls were also excluded 
from participating in the study because five males did not 
give consent/assent, three males were SCA patients, one was 
a known asthmatic patient, and one was on the steroid for 
SCA nephropathy.
Therefore, eighty HIV-infected subjects and eighty 
HIV-uninfected controls within the same age bracket of 
8–17 years were enrolled for the study and matched for 
age and socioeconomic class. Majority of the subjects and 
controls (70%) were pre/early adolescent (8–14 years) stage 
of life, while (30%) of the study participants were in middle 
adolescence (15–17 years). Forty‑eight of the subjects (60%) 
and 48 controls (60%), respectively, were in the lower 
socioeconomic class, while 32 (40%) were in the upper 
socioeconomic class, but none of the participants was from the 
middle class as depicted in Figure 1.
The frequencies of different variables of the subjects
Table 1 shows the clinical characteristics of the subjects. 
All the subjects were of mother-to-child transmission of 
HIV. Sixty‑four (80%) were on the first line of HAART, and 
only three had been on HAART for less than six months. 
Thirty-eight (47.5%) were HIV clinical staging 1, while 
one (1.25%) subject was in stage 4. The immunological status 
was assessed using CD4 count and it showed that majority 
of the subjects (49, 61.25%) had non significant (CD4 
count >500 cells/mm3) immunological staging and 5 (6.25%) 
had severe (CD4 count <200 cells/mm3) immunological 
staging. Additionally, more of the 43 (55.8%) subjects had 
unsuppressed viral load, while 34 (44.2%) had an suppressed 
viral load.
The physical growth profile of the study participants
Table 2 depicts a comparison of the physical growth of controls 
and subjects. The mean height for the controls and subjects 
were 1.515 ± 0.17 m and 1.420 ± 0.18 m, respectively. The 






















Figure 1: Social class and age profile of the study participants
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Table 2: Comparison of physical growth of the controls 
and subjects
Variables Participant t‑statistic P
Controls Subjects
Height (m) 1.515±0.170 1.420±0.180 3.350 0.001
Weight (kg) 42.210±12.950 35.090±12.480 3.540 0.001
BMI (kg/m2) 17.930±2.270 16.780±2.120 4.035 <0.001
Weight for 
age Z-score
0.238±0.730 −0.170±0.500 3.216 0.002
Height for 
age Z-score
0.069±1.400 −1.340±1.230 6.758 <0.001
BMI for age 
Z-score
−0.133±1.040 −0.780±1.220 3.628 <0.001
Values are mean±SD. BMI: Body mass index, Subjects: HIV‑positive, 
Controls: HIV‑negative, HIV: Human immunodeficiency virus, SD: 
Standard deviation
Table 3: Regression analysis of physical growth on social class, immunological stage, clinical stage, and duration on 
highly active antiretroviral therapy
Variable Physical growth Multivariate test
Z‑score for BMI Z‑score for height
β t (P) β t (P) Δ F P
Intercept −2.396 −2.135 (0.036) −1.247 −1.005 (0.318) 0.369 59.79 <0.001
Social class 0.161 0.625 (0.534) 0.250 0.880 (0.382) 0.991 0.312 0.733
CD 4 count
Not significant 1.270 2.074 (0.042) 0.900 1.330 (0.188) 0.774 3.194 0.006
Mild 1.061 1.645 (0.104) 0.139 0.195 (0.846)
Advance 0.850 1.269 (0.209) 0.624 0.842 (0.403)
Clinical stage
Stage I 1.359 1.061 (0.292) −0.533 −0.376 (0.708) 0.917 1.029 0.409
Stage II 0.799 0.614 (0.541) −0.830 −0.577 (0.566)
Stage III 0.642 0.512 (0.610) −0.965 −0.696 (0.489)
Duration on HAART 0.102 2.800 (0.007) 0.034 0.853 (0.396) 0.899 3.929 0.024
P<0.05 indicates a significant coefficient. β: Value of regression coefficient, Δ‑Wilks lambda statistic, t: t‑test statistics, F: F test statistic, P: Significant 
value, and the last each categorical variable is the reference category. BMI: Body mass index, HAART: Highly active antiretroviral therapy
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P = 0.001). Furthermore, the mean weight for controls 
and subjects were 42.21 ± 12.95 and 35.09 ± 12.48 kg, 
respectively. The difference between them was statistically 
significant (t = 3.540, P = 0.001).
Relationship between physical growth with social class, 
immunological status, clinical staging, and duration of 
highly active antiretroviral therapy in subjects
Table 3 shows a multivariate regression analysis of the physical 
growth on social class, immunological stages, clinical stage, 
and HAART duration. It shows that CD4 count and duration 
on HAART were significant. These indicate significant 
relationships between physical growth, CD4 count, and 
HAART duration but not with social class and clinical stages.
Relationship between viral load and physical growth
Table 4 shows the relationship between viral load and physical 
growth. There was a significant relationship between viral load 
and height for age. But there was no significant relationship 
between in contrast between viral load and BMI for age with 
P > 0.05.
dIscussIon
This study assessed HIV-infected males’ physical growth 
(subjects) compared with HIV-uninfected males (controls).
This study’s findings showed that stunting and underweight 
were more common in subjects than controls with P = 0.001. 
The difference in growth pattern between the two groups can 
be attributed to opportunistic infections (OIs) and immune 
dysfunction induced by HIV, resulting in increased protein 
metabolism and energy diversion away from growth. The 
subjects’ reduced height and weight in this study compared well 
with observations by Anyabolu et al.[29] among HIV-infected 
children in Ife, Oyo State, Nigeria, who also noted that 
more of the HIV-infected children were stunted, wasted, and 
underweight compared to the controls (P = 0.001). This finding 
in the index study was corroborated by Newel et al.[30] and 
Iloh et al.[31] who studied HIV-infected female adolescents in 
Enugu, Southeast Nigeria.
Isanaka et al.[32] suggested that disturbances to energy balance 
may be a factor in stunting of growth in HIV-infected children, 
while Newell et al.[30] found that OIs and HIV-induced immune 
dysfunction will lead to increased protein catabolism and 
diversion of nutrients away from growth.
The mean height in subjects was noted to be significantly 
lower compared to controls. The subjects’ chronicity of HIV 
infection may have negatively influenced their physical growth 
more than the control group. Ferrand et al.[33] stated that 
growth failure might be the distinguishing factor in subjects 
who have had the illness for a longer time than the uninfected 
group. These findings were corroborated by Majaliwa 
et al.[9] and Stagi et al.,[34] who found that growth in height 
is affected in individuals with HIV infection. Similar results 
Ogeh, et al.: Poor physical growth among perinatally HIV‑infected boys despite antiretroviral therapy in Abakaliki, South‑East Nigeria
Table 4: Relationship between viral load and physical growth for subjects
Viral load Height for age Total Measures of relationship
Stunting Normal Statistic Value P
Suppressed 2 32 34 χ2 9.283 0.002
Unsuppressed 15 28 43
Total 17 60 77
Viral load BMI for age Total Statistic Value P
Severe underweight Moderate underweight Normal Overweight
Suppressed 1 2 31 0 34 χ2 3.816 0.282
Unsuppressed 4 6 32 1 43
Total 5 8 63 1 77
P<0.05 implies a significant relationship. Subjects: HIV‑positive, BMI: Body mass index, HIV: Human immunodeficiency virus
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were also observed among perinatally HIV-infected males by 
Ferrand et al.[33] and Mbwile[17] in Zimbabwe and Tanzania, 
respectively, in Africa.
Similarly, the mean weight in subjects in this study was found 
to be significantly lower than controls. The survey by Majaliwa 
et al.[9] corroborated with this index study and observed that 
malnutrition which is a feature of HIV infection affects the 
hypothalamic–pituitary–gonadal axis resulting in decreased 
physical growth.
Additionally, BMI in this index study was significantly 
lower in the subjects than in the control groups. Mbwile[17] in 
Tanzania documented a similar finding where he documented 
lower BMI for age Z score in HIV infected than the HIV 
uninfected.
Thus, chronicity of HIV infection, malnutrition, and OIs may 
explain the reported difference in mean height, weight, BMI 
scores, and Z-scores between subjects and controls.
In the index study, there was also a significant positive 
association between physical growth and duration on 
HAART (P = 0.024). This finding may be that long duration 
on ART regimen may lead to the restoration of immune 
mechanism and reduction in OIs resulting in improvement of 
physical growth. This was corroborated by Brady et al.[35] that 
the main reason for the progression of HIV infection in children 
is the reduction of CD4 cells and increased viral load, which 
may result in OIs AIDS. These were similar to Ebonyi et al.’s 
findings,[36] which noted that after nine months on HAART, 
there was a significant reduction in the percentage of children 
with low BMI for age (P = 0.006). Only 2.5% still had low 
BMI after nine months of HAART compared to 18.2% at the 
beginning of HAART. Majority of subjects in this index study 
had been on HAART for an average of 5.8 years. This suggests 
that HAART improves physical growth but does not reverse 
growth failure caused by HIV.
conclusIon
HIV‑infected males have significantly lower weight, height, 
and BMI than HIV‑uninfected males. The effect of HIV on 
growth may persist despite antiretroviral therapy.
Limitation
The study was a case–control hospital-based study with only 
one assessment of physical growth. A prospective cohort study 
with multiple interval assessments would have given more 
information on the derangement in the physical growth of 
HIV-infected children.
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